
|Articles|March 1, 2004
Topical bexarotene benefits mycosis fungoides
Waikoloa, Hawaii - Bexarotene 1 percent gel (Targretin) is a useful alternative modality, offering advantages to other therapies, for the treatment of mycosis fungoides (MF), according to Joan Guitart, M.D., at the annual Hawaii Dermatology Seminar in January.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Phase 2 Nemolizumab Trial Opens for CPUO
5


















